INmune Bio, Inc.
NASDAQ:INMB
5.72 (USD) • At close November 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.155 | 0.374 | 0.181 | 0.011 | 77.688 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.155 | 0.374 | 0.181 | 0.011 | 77.688 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 20.273 | 17.067 | 20.543 | 5.917 | 3.282 | 1.105 | 0.435 | 0.101 | 0 |
| General & Administrative Expenses
| 9.623 | 9.258 | 8.791 | 6.321 | 6.016 | 11.335 | 0.546 | 0.126 | 0.195 |
| Selling & Marketing Expenses
| 0.163 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.147 |
| SG&A
| 9.623 | 9.258 | 8.791 | 6.321 | 6.016 | 11.335 | 0.546 | 0.126 | 0.049 |
| Other Expenses
| -0.267 | -1.348 | -1.187 | 0.129 | 0 | 0 | -0 | 0 | 0 |
| Operating Expenses
| 29.896 | 26.325 | 29.334 | 12.239 | 9.298 | 12.44 | 0.981 | 0.227 | 0.049 |
| Operating Income
| -29.741 | -25.951 | -29.153 | -12.228 | -7.756 | -12.44 | -0.981 | -0.227 | -0.049 |
| Operating Income Ratio
| -191.877 | -69.388 | -161.066 | -1,120.161 | -0.1 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -0.267 | -1.348 | -1.187 | 0.129 | 0.078 | 0 | 0.15 | -0.05 | 0 |
| Income Before Tax
| -30.008 | -27.299 | -30.34 | -12.099 | -7.678 | -12.44 | -0.831 | -0.277 | -0.049 |
| Income Before Tax Ratio
| -193.6 | -72.992 | -167.624 | -1,108.388 | -0.099 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -29.741 | 1.348 | -29.153 | -12.228 | 1.464 | -0.161 | -1.131 | -0.177 | 0 |
| Net Income
| -30.008 | -28.647 | -30.34 | -12.099 | -9.143 | -12.44 | -0.831 | -0.277 | -0.049 |
| Net Income Ratio
| -193.6 | -76.596 | -167.624 | -1,108.388 | -0.118 | 0 | 0 | 0 | 0 |
| EPS
| -1.67 | -1.6 | -1.88 | -1.01 | -0.89 | -1.11 | -0.074 | -0.025 | -0.004 |
| EPS Diluted
| -1.67 | -1.6 | -1.88 | -1.01 | -0.89 | -1.11 | -0.074 | -0.025 | -0.004 |
| EBITDA
| 0 | 0 | 0 | 0 | 0 | 0 | 0.15 | -0.05 | 0.147 |
| EBITDA Ratio
| -191.877 | -69.388 | -161.066 | -1,120.161 | -0.14 | 0 | 0 | 0 | 0 |